JAIME MURRAY: Open Payments
NPI 1437890480 · FLEMINGTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$943 in 55 payments from 17 companies in 2025. Trend: 2023 $1,809 · 2024 $1,818 · 2025 $943
Food & beverage: $943
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $209 |
| GlaxoSmithKline, LLC. | 17 | $186 |
| Regeneron Healthcare Solutions, Inc. | 5 | $82 |
| Lilly USA, LLC | 4 | $77 |
| Axsome Therapeutics, Inc. | 4 | $71 |
| Verona Pharma, Inc. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| HARMONY BIOSCIENCES LLC | 2 | $36 |
| Viatris Specialty LLC | 2 | $33 |
| Tactile Systems Technology Inc | 1 | $29 |
Products named: NUCALA, DUPIXENT, FASENRA, ZEPBOUND, TEZSPIRE, Sunosi, Ohtuvayre, BREZTRI.
Industry payments across NJ — which companies pay providers there.
